Fig. 7: Filanesib reduces HB tumor growth rate in vivo. | npj Precision Oncology

Fig. 7: Filanesib reduces HB tumor growth rate in vivo.

From: Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma

Fig. 7: Filanesib reduces HB tumor growth rate in vivo.

Changes in tumor volume and bodyweight of mice treated with oral 20 mg/kg filanesib every fourth day (red squares), 30 mg/kg luminespib three times per week (blue triangles) or with vehicle (black circles) are shown (left panel, A–E). Each point is the mean ± SEM. Each of the five study arms included three mice. Bodyweights are shown in right panel (A–E).

Back to article page